anti-VEGF antibody

Anti-VEGF antibody

Anti-VEGF antibodies are antibody drugs that target VEGF (vascular endothelial growth factor). VEGF is a major factor that promotes tumor angiogenesis, and anti-VEGF antibodies work by binding to VEGF and inhibiting its signaling to VEGF receptors. This, in turn,Inhibit blood supply to the tumor and control tumor growth.and are widely used as drug discovery classes. Their main indications include colon cancer, lung cancer, and renal cell carcinoma, and they play an important role in the drug therapy of various cancer types.

Representative examples of anti-VEGF antibodies

Bevacizumab (Avastin)

Bevacizumab (Avastin) is a representative anti-VEGF antibody that targets VEGF-A. By binding to VEGF-A and inhibiting angiogenesis signaling,A prime example that drove the development of anti-VEGF antibodies as a standard for angiogenesis inhibitionand is widely used in many types of cancer today.

Ramucirumab (Cyramza)

Ramucirumab (Cyramza) is an antibody drug that targets VEGFR2 (vascular endothelial growth factor receptor 2). By binding to the receptor instead of VEGF itself, it inhibits signal transduction.Mechanism of action different from bevacizumab, which targets ligandsinhibits angiogenesis.

Aflibercept (Zaltrap)

Aflibercept (Zaltrap) is an angiogenesis inhibitor classified as a VEGF Trap formulation. It binds to PlGF (placental growth factor) in addition to VEGF-A,Ligand trap that captures multiple ligands to prevent binding to the receptorIt has the following characteristics.

Key challenges in anti-VEGF antibody development

Drug resistance through compensatory pathways of angiogenesis

Even when VEGF signaling is inhibited by anti-VEGF antibodies, tumors may compensate by maintaining angiogenesis through the activation of alternative angiogenic pathways such as FGF and PDGF.Because VEGF monotherapy doesn't lead to sustained efficacy, evaluation of effectiveness using resistance models is important.Pharmacodynamics(PD) Studies

Individualized response to angiogenesis dependence

Tumor dependence on VEGF varies between patients, and biomarkers that predict treatment effectiveness are not well-established. Additionally, differences in the tumor microenvironment (TME) also affect drug efficacy.Evaluation using patient-derived models and angiogenesis models is important for appropriate drug development and efficacy prediction.it is thought that.

Evaluation of effects on normal blood vessels and human extrapolation

Because VEGF is important for the maintenance of normal blood vessels as well as tumor blood vessels, issues such as hypertension, delayed wound healing, bleeding, and thrombosis can arise with anti-VEGF antibodies.Safety evaluation using disease models that consider human translatability is important for clinical application.It is considered.

Non-clinical evaluations required for anti-VEGF antibody development

Construct a pathological model capable of reproducing angiogenesis

In the preclinical evaluation of anti-VEGF antibodies, in addition to tumor angiogenesis models, models such as PDX models, organoids, and tumor microenvironment (TME) models are utilized.By combining different disease models, angiogenesis and drug efficacy can be evaluated in an environment closer to actual clinical practice.It is possible.

Multifaceted evaluation of anti-angiogenic effects

In preclinical studies of anti-VEGF antibodies, efficacy is evaluated by assessing vascular density, target engagement, and various biomarkers, in addition to incorporating digital pathology and imaging analysis.By integrating multiple evaluation systems, the anti-angiogenic effect can be analyzed multidimensionally and with high precision.is important.

Integrate pharmacokinetics and intratumoral distribution for evaluation.

In the development of anti-VEGF antibodies, in addition to PK evaluation, we analyze intratumoral distribution, vascular permeability, and antibody pharmacokinetics to confirm whether the drug sufficiently reaches the target tissue.By integrally analyzing PK/PD evaluation and drug efficacy, we can better predict effectiveness.Can be done.

Evaluate safety from the early stages of development

In addition to side effects such as hypertension, bleeding, thrombosis, and delayed wound healing, the expression of ADAs (anti-drug antibodies) and long-term safety are also important evaluation items for anti-VEGF antibodies.Developing and implementing safety evaluation strategies tailored to the modality from the early stages of development leads to successful clinical development.it is thought that.

Key points when choosing a contract research organization (CRO) for non-clinical studies

In the development of anti-VEGF antibodies, it is important to integrally advance the process from the establishment of a disease model to the evaluation of efficacy, safety, and PK/PD. While advancements in new modalities and combination therapies are expected in the future, the selection of a strategic CRO with an evaluation system that considers human translatability will be key to successful development.